{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:02:59Z","timestamp":1791072179281,"version":"4.1.0"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T00:00:00Z","timestamp":1749340800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T00:00:00Z","timestamp":1749340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Local intraprostatic recurrence is one of the important recurrence patterns following definitive intensity-modulated radiation therapy (IMRT) that continues to pose a significant challenge. The technological advances in radiation therapy now facilitate selective dose escalation for intraprostatic dominant lesions (IPDLs). A novel IMRT method, focal boosting using simultaneous integrated boost IMRT (FB-SIB-IMRT), can achieve selective dose escalation to IPDLs while minimizing any increase in dose to organs at risk (OARs). In addition, this method is applied to hypofractionated EBRT, including stereotactic body radiation therapy (SBRT). To date, numerous prospective studies have reported clinical results of FB-SIB-IMRT for non-metastatic PCa. In this review, we describe and summarize clinical outcomes of previous studies, including the technological background, current status, and future perspectives regarding focal dose escalation for IPDLs using IMRT for non-metastatic PCa.<\/jats:p>","DOI":"10.1007\/s10147-025-02799-x","type":"journal-article","created":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T08:11:56Z","timestamp":1749370316000},"page":"1448-1462","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Narrative review of focal boost to intraprostatic dominant lesion in intensity-modulated radiation therapy for localized or locally advanced prostate cancer"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7098-6221","authenticated-orcid":false,"given":"Rihito","family":"Aizawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Mizowaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,8]]},"reference":[{"key":"2799_CR1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"2799_CR2","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1007\/s10147-024-02575-3","volume":"29","author":"T Sasaki","year":"2024","unstructured":"Sasaki T, Higashi T, Inoue T (2024) Urological cancer statistics on incidence from 1975 to 2019 and mortality from 1958 to 2022 in Japan. Int J Clin Oncol 29:1088\u20131095","journal-title":"Int J Clin Oncol"},{"key":"2799_CR3","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/iju.15545","volume":"31","author":"Y Kohjimoto","year":"2024","unstructured":"Kohjimoto Y, Uemura H, Yoshida M et al (2024) Japanese clinical practice guidelines for prostate cancer 2023. Int J Urol 31:1180\u20131222","journal-title":"Int J Urol"},{"key":"2799_CR4","unstructured":"National Comprehensive Cancer Network (2024) NCCN guidelines; prostate cancer version 4. 2024. The category of prostate cancer. https:\/\/www.nccnorg\/guidelines\/category_1."},{"key":"2799_CR5","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1111\/iju.14011","volume":"26","author":"K Hatano","year":"2019","unstructured":"Hatano K, Tohyama N, Kodama T et al (2019) Current status of intensity-modulated radiation therapy for prostate cancer: history, clinical results and future directions. Int J Urol 26:775\u2013784","journal-title":"Int J Urol"},{"key":"2799_CR6","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1200\/JCO.20.02873","volume":"39","author":"LGW Kerkmeijer","year":"2021","unstructured":"Kerkmeijer LGW, Groen VH, Pos FJ et al (2021) Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial. J Clin Oncol 39:787\u2013796","journal-title":"J Clin Oncol"},{"key":"2799_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2024.101629","volume":"9","author":"SN Regan","year":"2024","unstructured":"Regan SN, Dykstra M, Yin H et al (2024) Microboost in localized prostate cancer: analysis of a statewide quality consortium. Adv Radiat Oncol 9:101629","journal-title":"Adv Radiat Oncol"},{"key":"2799_CR8","doi-asserted-by":"publisher","first-page":"e787","DOI":"10.1016\/j.ijrobp.2011.11.030","volume":"82","author":"E Arrayeh","year":"2012","unstructured":"Arrayeh E, Westphalen AC, Kurhanewicz J et al (2012) Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study. Int J Radiat Oncol Biol Phys 82:e787-793","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2799_CR9","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1016\/j.ijrobp.2011.05.035","volume":"82","author":"S Chopra","year":"2012","unstructured":"Chopra S, Toi A, Taback N et al (2012) Pathological predictors for site of local recurrence after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 82:e441-448","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2799_CR10","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.ijrobp.2021.12.164","volume":"112","author":"S Raman","year":"2022","unstructured":"Raman S, Keyes M, Oh J et al (2022) Patterns of prostate cancer recurrence after brachytherapy determined by prostate-specific membrane antigen-positron emission tomography and computed tomography imaging. Int J Radiat Oncol Biol Phys 112:1126\u20131134","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2799_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2024.101489","volume":"9","author":"R Aizawa","year":"2024","unstructured":"Aizawa R, Otani T, Ogata T et al (2024) Spatial pattern of intraprostatic recurrence after definitive external-beam radiation therapy for prostate cancer: implications for focal boost to intraprostatic dominant lesion. Adv Radiat Oncol 9:101489","journal-title":"Adv Radiat Oncol"},{"key":"2799_CR12","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s12149-021-01704-6","volume":"36","author":"T Otani","year":"2022","unstructured":"Otani T, Saga T, Ishimori T et al (2022) Detection efficacy of PET\/CT with (18)F-FSU-880 in patients with suspected recurrent prostate cancer: a prospective single-center study. Ann Nucl Med 36:302\u2013309","journal-title":"Ann Nucl Med"},{"key":"2799_CR13","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1097\/COC.0b013e318209cd8f","volume":"35","author":"E Ippolito","year":"2012","unstructured":"Ippolito E, Mantini G, Morganti AG et al (2012) Intensity-modulated radiotherapy with simultaneous integrated boost to dominant intraprostatic lesion: preliminary report on toxicity. Am J Clin Oncol 35:158\u2013162","journal-title":"Am J Clin Oncol"},{"key":"2799_CR14","doi-asserted-by":"publisher","first-page":"e423","DOI":"10.1016\/j.ijrobp.2011.01.048","volume":"81","author":"WW Wong","year":"2011","unstructured":"Wong WW, Schild SE, Vora SA et al (2011) Image-guided radiotherapy for prostate cancer: a prospective trial of concomitant boost using indium-111-capromab pendetide (ProstaScint) imaging. Int J Radiat Oncol Biol Phys 81:e423-429","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2799_CR15","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.clon.2015.09.006","volume":"28","author":"J Uzan","year":"2016","unstructured":"Uzan J, Nahum AE, Syndikus I (2016) Prostate dose-painting radiotherapy and radiobiological guided optimisation enhances the therapeutic ratio. Clin Oncol (R Coll Radiol) 28:165\u2013170","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2799_CR16","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/j.ijrobp.2010.10.075","volume":"82","author":"R Miralbell","year":"2012","unstructured":"Miralbell R, Roberts SA, Zubizarreta E et al (2012) Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: alpha\/beta = 1.4 (0.9\u20132.2) Gy. Int J Radiat Oncol Biol Phys 82:e17-24","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2799_CR17","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1200\/JCO.18.01097","volume":"36","author":"SC Morgan","year":"2018","unstructured":"Morgan SC, Hoffman K, Loblaw DA et al (2018) Hypofractionated radiation therapy for localized prostate cancer: an ASTRO, ASCO, and AUA evidence-based guideline. J Clin Oncol 36:3411\u20133434","journal-title":"J Clin Oncol"},{"key":"2799_CR18","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","volume":"394","author":"A Widmark","year":"2019","unstructured":"Widmark A, Gunnlaugsson A, Beckman L et al (2019) Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet 394:385\u2013395","journal-title":"Lancet"},{"key":"2799_CR19","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","volume":"391","author":"N van As","year":"2024","unstructured":"van As N, Griffin C, Tree A et al (2024) Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer. N Engl J Med 391:1413\u20131425","journal-title":"N Engl J Med"},{"key":"2799_CR20","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1080\/0284186X.2023.2213443","volume":"62","author":"T Hirata","year":"2023","unstructured":"Hirata T, Suzuki O, Otani K et al (2023) Increased toxicities associated with dose escalation of stereotactic body radiation therapy in prostate cancer: results from a phase I\/II study. Acta Oncol 62:488\u2013494","journal-title":"Acta Oncol"},{"key":"2799_CR21","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.21873\/anticanres.14162","volume":"40","author":"R Nakamura","year":"2020","unstructured":"Nakamura R, Hirata T, Suzuki O et al (2020) Stereotactic body radiotherapy using CyberKnife(R) for localized low- and intermediate-risk prostate cancer: initial report on a phase I\/II trial. Anticancer Res 40:2053\u20132057","journal-title":"Anticancer Res"},{"key":"2799_CR22","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13014-022-02037-y","volume":"17","author":"S Kawakami","year":"2022","unstructured":"Kawakami S, Tsumura H, Satoh T et al (2022) A phase II trial of stereotactic body radiotherapy in 4 fractions for patients with localized prostate cancer. Radiat Oncol 17:67","journal-title":"Radiat Oncol"},{"key":"2799_CR23","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13014-021-01834-1","volume":"16","author":"M Ogita","year":"2021","unstructured":"Ogita M, Yamashita H, Nozawa Y et al (2021) Phase II study of stereotactic body radiotherapy with hydrogel spacer for prostate cancer: acute toxicity and propensity score-matched comparison. Radiat Oncol 16:107","journal-title":"Radiat Oncol"},{"key":"2799_CR24","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1093\/jjco\/hyab094","volume":"51","author":"M Ito","year":"2021","unstructured":"Ito M, Yoshioka Y, Takase Y et al (2021) Stereotactic body radiation therapy for Japanese patients with localized prostate cancer: 2-year results and predictive factors for acute genitourinary toxicities. Jpn J Clin Oncol 51:1253\u20131260","journal-title":"Jpn J Clin Oncol"},{"key":"2799_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/iju.15507","author":"K Tanabe","year":"2024","unstructured":"Tanabe K, Kobayashi S, Tamiya T et al (2024) Risk factors for the long-term persistent genitourinary toxicity after stereotactic body radiation therapy for localized prostate cancer: a single-center, retrospective study of 306 patients. Int J Urol. https:\/\/doi.org\/10.1111\/iju.15507","journal-title":"Int J Urol"},{"key":"2799_CR26","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.clon.2016.09.009","volume":"29","author":"E Onjukka","year":"2017","unstructured":"Onjukka E, Uzan J, Baker C et al (2017) Twenty fraction prostate radiotherapy with intra-prostatic boost: results of a pilot study. Clin Oncol (R Coll Radiol) 29:6\u201314","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2799_CR27","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.ijrobp.2019.11.402","volume":"106","author":"JR Murray","year":"2020","unstructured":"Murray JR, Tree AC, Alexander EJ et al (2020) Standard and hypofractionated dose escalation to intraprostatic tumor nodules in localized prostate cancer: efficacy and toxicity in the DELINEATE trial. Int J Radiat Oncol Biol Phys 106:715\u2013724","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2799_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2022.09.058","author":"AC Tree","year":"2022","unstructured":"Tree AC, Satchwell L, Alexander E et al (2022) Standard and hypofractionated dose escalation to intraprostatic tumor nodules in localized prostate cancer: 5-year efficacy and toxicity in the DELINEATE trial. Int J Radiat Oncol Biol Phys. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.09.058","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2799_CR29","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.radonc.2020.03.015","volume":"147","author":"C Draulans","year":"2020","unstructured":"Draulans C, van der Heide UA, Haustermans K et al (2020) Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer. Radiother Oncol 147:92\u201398","journal-title":"Radiother Oncol"},{"key":"2799_CR30","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ijrobp.2018.09.023","volume":"103","author":"FG Herrera","year":"2019","unstructured":"Herrera FG, Valerio M, Berthold D et al (2019) 50-Gy Stereotactic body radiation therapy to the dominant intraprostatic nodule: results from a phase 1a\/b trial. Int J Radiat Oncol Biol Phys 103:320\u2013334","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2799_CR31","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s12032-020-01397-3","volume":"37","author":"G Marvaso","year":"2020","unstructured":"Marvaso G, Gugliandolo SG, Bellerba F et al (2020) Phase II prospective trial \u201cGive Me Five\u201d short-term high precision radiotherapy for early prostate cancer with simultaneous boost to the dominant intraprostatic lesion: the impact of toxicity on quality of life (AIRC IG-13218). Med Oncol 37:74","journal-title":"Med Oncol"},{"key":"2799_CR32","first-page":"88","volume":"25","author":"L Nicholls","year":"2020","unstructured":"Nicholls L, Suh YE, Chapman E et al (2020) Stereotactic radiotherapy with focal boost for intermediate and high-risk prostate cancer: initial results of the SPARC trial. Clin Transl Radiat Oncol 25:88\u201393","journal-title":"Clin Transl Radiat Oncol"},{"key":"2799_CR33","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ijrobp.2024.03.009","volume":"120","author":"B Yasar","year":"2024","unstructured":"Yasar B, Suh YE, Chapman E et al (2024) Simultaneous focal boost with stereotactic radiation therapy for localized intermediate- to high-risk prostate cancer: primary outcomes of the SPARC phase 2 trial. Int J Radiat Oncol Biol Phys 120:49\u201358","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2799_CR34","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00066-023-02189-0","volume":"200","author":"F Deodato","year":"2024","unstructured":"Deodato F, Ferro M, Bonome P et al (2024) Stereotactic body radiotherapy (SIB-VMAT technique) to dominant intraprostatic lesion (DIL) for localized prostate cancer: a dose-escalation trial (DESTROY-4). Strahlenther Onkol 200:239\u2013249","journal-title":"Strahlenther Onkol"},{"key":"2799_CR35","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.adro.2018.09.007","volume":"4","author":"AM McDonald","year":"2019","unstructured":"McDonald AM, Dobelbower MC, Yang ES et al (2019) Prostate stereotactic body radiation therapy with a focal simultaneous integrated boost: acute toxicity and dosimetry results from a prospective trial. Adv Radiat Oncol 4:90\u201395","journal-title":"Adv Radiat Oncol"},{"key":"2799_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2023.05.004","author":"JA Maas","year":"2023","unstructured":"Maas JA, Dobelbower MC, Yang ES et al (2023) Prostate stereotactic body radiation therapy with a focal simultaneous integrated boost: 5-year toxicity and biochemical recurrence results from a prospective trial. Pract Radiat Oncol. https:\/\/doi.org\/10.1016\/j.prro.2023.05.004","journal-title":"Pract Radiat Oncol"},{"key":"2799_CR37","doi-asserted-by":"publisher","first-page":"20220803","DOI":"10.1259\/bjr.20220803","volume":"96","author":"M Cloitre","year":"2023","unstructured":"Cloitre M, Valerio M, Mampuya A et al (2023) Toxicity, quality of life, and PSA control after 50 Gy stereotactic body radiation therapy to the dominant intraprostatic nodule with the use of a rectal spacer: results of a phase I\/II study. Br J Radiol 96:20220803","journal-title":"Br J Radiol"},{"key":"2799_CR38","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1016\/S0167-8140(23)89920-0","volume":"181","author":"WL Ong","year":"2023","unstructured":"Ong WL, Cheung P, Chung H et al (2023) Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion\u2014results from the 2SMART phase 2 trial. Radiother Oncol 181:S18","journal-title":"Radiother Oncol"},{"key":"2799_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109713.109713","author":"L De Cock","year":"2023","unstructured":"De Cock L, Draulans C, Pos FJ et al (2023) From once-weekly to semi-weekly whole prostate gland stereotactic radiotherapy with focal boosting: primary endpoint analysis of the multicenter phase II hypo-FLAME 2.0 trial. Radiother Oncol. https:\/\/doi.org\/10.1016\/j.radonc.2023.109713.109713","journal-title":"Radiother Oncol"},{"key":"2799_CR40","doi-asserted-by":"publisher","first-page":"5795","DOI":"10.3390\/cancers13225795","volume":"13","author":"C Zamboglou","year":"2021","unstructured":"Zamboglou C, Spohn SKB, Adebahr S et al (2021) PSMA-PET\/MRI-based focal dose escalation in patients with primary prostate cancer treated with stereotactic body radiation therapy (HypoFocal-SBRT): study protocol of a randomized, multicentric phase III trial. Cancers (Basel) 13:5795","journal-title":"Cancers (Basel)"},{"key":"2799_CR41","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/jrr\/rry060","volume":"59","author":"K Nakamura","year":"2018","unstructured":"Nakamura K, Ikeda I, Inokuchi H et al (2018) A pilot study of highly hypofractionated intensity-modulated radiation therapy over 3 weeks for localized prostate cancer. J Radiat Res 59:656\u2013663","journal-title":"J Radiat Res"},{"key":"2799_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2023.06.004","author":"K Nakamura","year":"2023","unstructured":"Nakamura K, Ikeda I, Inokuchi H et al (2023) Long-term outcomes of a prospective study on highly hypofractionated intensity modulated radiation therapy for localized prostate cancer for 3 weeks. Pract Radiat Oncol. https:\/\/doi.org\/10.1016\/j.prro.2023.06.004","journal-title":"Pract Radiat Oncol"},{"key":"2799_CR43","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jama.280.11.969","volume":"280","author":"AV D'Amico","year":"1998","unstructured":"D\u2019Amico AV, Whittington R, Malkowicz SB et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969\u2013974","journal-title":"JAMA"},{"key":"2799_CR44","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/cas.16429","volume":"116","author":"R Aizawa","year":"2025","unstructured":"Aizawa R, Ogata T, Goto T et al (2025) Highly hypofractionated biaxially rotational dynamic radiation therapy (BROAD-RT) for high-risk prostate cancer. Cancer Sci 116:1004\u20131011","journal-title":"Cancer Sci"},{"key":"2799_CR45","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.1016\/j.prro.2023.10.006","volume":"14","author":"N Camden","year":"2024","unstructured":"Camden N, Blumenfeld P, Roy S et al (2024) Multiparametric magnetic resonance imaging- guided dose-escalated radiation therapy for localized prostate cancer: a prospective phase 2 trial. Pract Radiat Oncol 14:e132\u2013e140","journal-title":"Pract Radiat Oncol"},{"key":"2799_CR46","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.ijrobp.2010.04.025","volume":"79","author":"P Ost","year":"2011","unstructured":"Ost P, Speleers B, De Meerleer G et al (2011) Volumetric arc therapy and intensity-modulated radiotherapy for primary prostate radiotherapy with simultaneous integrated boost to intraprostatic lesion with 6 and 18 MV: a planning comparison study. Int J Radiat Oncol Biol Phys 79:920\u2013926","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2799_CR47","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.prro.2023.08.017","volume":"14","author":"A Shimomura","year":"2024","unstructured":"Shimomura A, Wu T, Rusu I et al (2024) Monitoring intrafraction motion of the prostate during radiation therapy: suggested practice points from a focused review. Pract Radiat Oncol 14:146\u2013153","journal-title":"Pract Radiat Oncol"},{"key":"2799_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/acm2.13707","volume":"23","author":"D Higuchi","year":"2022","unstructured":"Higuchi D, Ono T, Kakino R et al (2022) Evaluation of internal margins for prostate for step and shoot intensity-modulated radiation therapy and volumetric modulated arc therapy using different margin formulas. J Appl Clin Med Phys 23:e13707","journal-title":"J Appl Clin Med Phys"},{"key":"2799_CR49","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.eururo.2015.08.052","volume":"69","author":"JC Weinreb","year":"2016","unstructured":"Weinreb JC, Barentsz JO, Choyke PL et al (2016) PI-RADS prostate imaging\u2014reporting and data system: 2015, version 2. Eur Urol 69:16\u201340","journal-title":"Eur Urol"},{"key":"2799_CR50","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.eururo.2015.12.053","volume":"70","author":"M Eiber","year":"2016","unstructured":"Eiber M, Weirich G, Holzapfel K et al (2016) Simultaneous (68)Ga-PSMA HBED-CC PET\/MRI improves the localization of primary prostate cancer. Eur Urol 70:829\u2013836","journal-title":"Eur Urol"},{"key":"2799_CR51","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s00259-015-3257-5","volume":"43","author":"C Zamboglou","year":"2016","unstructured":"Zamboglou C, Wieser G, Hennies S et al (2016) MRI versus (6)(8)Ga-PSMA PET\/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer. Eur J Nucl Med Mol Imaging 43:889\u2013897","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2799_CR52","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1007\/s00259-020-04827-6","volume":"47","author":"S Spohn","year":"2020","unstructured":"Spohn S, Jaegle C, Fassbender TF et al (2020) Intraindividual comparison between (68)Ga-PSMA-PET\/CT and mpMRI for intraprostatic tumor delineation in patients with primary prostate cancer: a retrospective analysis in 101 patients. Eur J Nucl Med Mol Imaging 47:2796\u20132803","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2799_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2023.101241","volume":"8","author":"JM Floberg","year":"2023","unstructured":"Floberg JM, Wells SA, Ojala D et al (2023) Using (18)F-DCFPyL prostate-specific membrane antigen-directed positron emission tomography\/magnetic resonance imaging to define intraprostatic boosts for prostate stereotactic body radiation therapy. Adv Radiat Oncol 8:101241","journal-title":"Adv Radiat Oncol"},{"key":"2799_CR54","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.ijrobp.2023.07.004","volume":"117","author":"AJ Lui","year":"2023","unstructured":"Lui AJ, Kallis K, Zhong AY et al (2023) ReIGNITE radiation therapy boost: a prospective, international study of radiation oncologists\u2019 accuracy in contouring prostate tumors for focal radiation therapy boost on conventional magnetic resonance imaging alone or with assistance of restriction spectrum imaging. Int J Radiat Oncol Biol Phys 117:1145\u20131152","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2799_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11604-024-01646-9","volume":"43","author":"T Otani","year":"2025","unstructured":"Otani T, Nakamoto R, Umeoka S et al (2025) PSMA PET\/CT imaging and its application to prostate cancer treatment. Jpn J Radiol 43:1\u201312","journal-title":"Jpn J Radiol"},{"key":"2799_CR56","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.ijrobp.2022.04.020","volume":"113","author":"C Zamboglou","year":"2022","unstructured":"Zamboglou C, Spohn SKB, Ruf J et al (2022) PSMA-PET- and MRI-based focal dose escalated radiation therapy of primary prostate cancer: planned safety analysis of a nonrandomized 2-armed phase 2 trial (ARO2020-01). Int J Radiat Oncol Biol Phys 113:1025\u20131035","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2799_CR57","doi-asserted-by":"publisher","first-page":"e201","DOI":"10.1016\/j.prro.2021.09.008","volume":"12","author":"T Eade","year":"2022","unstructured":"Eade T, Kneebone A, Hruby G et al (2022) Early outcomes and decision regret using PSMA\/MRI-guided focal boost for prostate cancer SBRT. Pract Radiat Oncol 12:e201\u2013e206","journal-title":"Pract Radiat Oncol"},{"key":"2799_CR58","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/jmri.27623","volume":"54","author":"CH Feng","year":"2021","unstructured":"Feng CH, Conlin CC, Batra K et al (2021) Voxel-level classification of prostate cancer on magnetic resonance imaging: improving accuracy using four-compartment restriction spectrum imaging. J Magn Reson Imaging 54:975\u2013984","journal-title":"J Magn Reson Imaging"},{"key":"2799_CR59","doi-asserted-by":"publisher","first-page":"6499","DOI":"10.21873\/anticanres.14672","volume":"40","author":"M Buwenge","year":"2020","unstructured":"Buwenge M, Alitto AR, Cilla S et al (2020) Simultaneous integrated radiotherapy boost to the dominant intraprostatic lesion: final results of a phase I\/II trial. Anticancer Res 40:6499\u20136503","journal-title":"Anticancer Res"},{"key":"2799_CR60","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.meddos.2015.04.003","volume":"40","author":"I Ikeda","year":"2015","unstructured":"Ikeda I, Mizowaki T, Ono T et al (2015) Effect of intrafractional prostate motion on simultaneous boost intensity-modulated radiotherapy to the prostate: a simulation study based on intrafractional motion in the prone position. Med Dosim 40:325\u2013332","journal-title":"Med Dosim"},{"key":"2799_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110568","volume":"201","author":"C Draulans","year":"2024","unstructured":"Draulans C, Haustermans K, Pos FJ et al (2024) Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial. Radiother Oncol 201:110568","journal-title":"Radiother Oncol"},{"key":"2799_CR62","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ijrobp.2011.11.047","volume":"84","author":"MJ Zelefsky","year":"2012","unstructured":"Zelefsky MJ, Kollmeier M, Cox B et al (2012) Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 84:125\u2013129","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2799_CR63","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.ijrobp.2018.07.2006","volume":"102","author":"R de Crevoisier","year":"2018","unstructured":"de Crevoisier R, Bayar MA, Pommier P et al (2018) Daily versus weekly prostate cancer image guided radiation therapy: phase 3 multicenter randomized trial. Int J Radiat Oncol Biol Phys 102:1420\u20131429","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2799_CR64","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10147-023-02456-1","volume":"29","author":"R Aizawa","year":"2024","unstructured":"Aizawa R, Inokuchi H, Ikeda I et al (2024) Impact of prostate position-based image-guidance in intensity-modulated radiation therapy for localized prostate cancer. Int J Clin Oncol 29:325\u2013332","journal-title":"Int J Clin Oncol"},{"key":"2799_CR65","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-017-1174-2","author":"K Nakamura","year":"2017","unstructured":"Nakamura K, Mizowaki T, Inokuchi H et al (2017) Decreased acute toxicities of intensity-modulated radiation therapy for localized prostate cancer with prostate-based versus bone-based image guidance. Int J Clin Oncol. https:\/\/doi.org\/10.1007\/s10147-017-1174-2","journal-title":"Int J Clin Oncol"},{"key":"2799_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2024.101612","volume":"9","author":"I Serizawa","year":"2024","unstructured":"Serizawa I, Kozuka T, Soyano T et al (2024) Clinical and dosimetric comparison between non-image guided radiation therapy and fiducial-based image guided radiation therapy with or without reduced margin in intensity modulated radiation therapy for prostate cancer. Adv Radiat Oncol 9:101612","journal-title":"Adv Radiat Oncol"},{"key":"2799_CR67","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1001\/jamaoncol.2022.6558","volume":"9","author":"AU Kishan","year":"2023","unstructured":"Kishan AU, Ma TM, Lamb JM et al (2023) Magnetic resonance imaging-guided vs computed tomography-guided stereotactic body radiotherapy for prostate cancer: the MIRAGE randomized clinical trial. JAMA Oncol 9:365\u2013373","journal-title":"JAMA Oncol"},{"key":"2799_CR68","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.radonc.2014.02.009","volume":"111","author":"B Engels","year":"2014","unstructured":"Engels B, Soete G, Gevaert T et al (2014) Impact of planning target volume margins and rectal distention on biochemical failure in image-guided radiotherapy of prostate cancer. Radiother Oncol 111:106\u2013109","journal-title":"Radiother Oncol"},{"key":"2799_CR69","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s10147-024-02517-z","volume":"29","author":"K Nakamura","year":"2024","unstructured":"Nakamura K, Nihei K, Saito Y et al (2024) A Japanese multi-institutional phase II study of moderate hypofractionated intensity-modulated radiotherapy with image-guided technique for prostate cancer. Int J Clin Oncol 29:847\u2013852","journal-title":"Int J Clin Oncol"},{"key":"2799_CR70","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-024-02333-4","author":"Y Tsurugai","year":"2024","unstructured":"Tsurugai Y, Takeda A, Sanuki N et al (2024) Toxicity profile and clinical outcomes of stereotactic body radiotherapy with a focal boost without fiducials or perirectal hydrogel spacer for localized prostate cancer. Strahlenther Onkol. https:\/\/doi.org\/10.1007\/s00066-024-02333-4","journal-title":"Strahlenther Onkol"},{"key":"2799_CR71","doi-asserted-by":"publisher","first-page":"20230717","DOI":"10.1259\/bjr.20230717","volume":"96","author":"H Grewal","year":"2023","unstructured":"Grewal H, Kedar R, Dhillon G et al (2023) SpaceOAR hydrogel complications in prostate cancer. Br J Radiol 96:20230717","journal-title":"Br J Radiol"},{"key":"2799_CR72","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1002\/cncr.34836","volume":"129","author":"JE Leeman","year":"2023","unstructured":"Leeman JE, Shin KY, Chen YH et al (2023) Acute toxicity comparison of magnetic resonance-guided adaptive versus fiducial or computed tomography-guided non-adaptive prostate stereotactic body radiotherapy: a systematic review and meta-analysis. Cancer 129:3044\u20133052","journal-title":"Cancer"},{"key":"2799_CR73","doi-asserted-by":"publisher","first-page":"260","DOI":"10.5603\/RPOR.a2022.0041","volume":"27","author":"P Dankulchai","year":"2022","unstructured":"Dankulchai P, Sittiwong W, Teerasamit W (2022) Feasibility and safety of definite volumetric modulated arc therapy with simultaneous integrated boost to the dominant intraprostatic lesion in patients with unfavorable intermediate to high-risk prostate cancer. Rep Pract Oncol Radiother 27:260\u2013267","journal-title":"Rep Pract Oncol Radiother"},{"key":"2799_CR74","doi-asserted-by":"publisher","first-page":"20210683","DOI":"10.1259\/bjr.20210683","volume":"95","author":"A Zapatero","year":"2022","unstructured":"Zapatero A, Roch M, Castro Tejero P et al (2022) MRI-guided focal boost to dominant intraprostatic lesion using volumetric modulated arc therapy in prostate cancer. Results of a phase II trial. Br J Radiol 95:20210683","journal-title":"Br J Radiol"},{"key":"2799_CR75","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.radonc.2015.05.011","volume":"115","author":"NG Zaorsky","year":"2015","unstructured":"Zaorsky NG, Palmer JD, Hurwitz MD et al (2015) What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation. Radiother Oncol 115:295\u2013300","journal-title":"Radiother Oncol"},{"key":"2799_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110535.110535","author":"K Menne Guricova","year":"2024","unstructured":"Menne Guricova K, Pos FJ, Schoots IG et al (2024) Intra-prostatic recurrences after radiotherapy with focal boost: location and dose mapping in the FLAME trial. Radiother Oncol. https:\/\/doi.org\/10.1016\/j.radonc.2024.110535.110535","journal-title":"Radiother Oncol"},{"key":"2799_CR77","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.radonc.2021.12.027","volume":"167","author":"VH Groen","year":"2022","unstructured":"Groen VH, van Schie M, Zuithoff NPA et al (2022) Urethral and bladder dose-effect relations for late genitourinary toxicity following external beam radiotherapy for prostate cancer in the FLAME trial. Radiother Oncol 167:127\u2013132","journal-title":"Radiother Oncol"},{"key":"2799_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2025.01.008","author":"KR Patel","year":"2025","unstructured":"Patel KR, Pra AD, Huang EP et al (2025) The determinants of toxicity in the treatment of prostate cancer with a focal, intraprostatic \u201cmicroboost.\u201d Int J Radiat Oncol Biol Phys. https:\/\/doi.org\/10.1016\/j.ijrobp.2025.01.008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2799_CR79","volume":"51","author":"JL Guevelou","year":"2025","unstructured":"Guevelou JL, Sargos P, Ost P et al (2025) Urethra-sparing prostate cancer radiotherapy: current practices and future insights from an international survey. Clin Transl Radiat Oncol 51:100907","journal-title":"Clin Transl Radiat Oncol"},{"key":"2799_CR80","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.radonc.2021.06.033","volume":"162","author":"VH Groen","year":"2021","unstructured":"Groen VH, Zuithoff NPA, van Schie M et al (2021) Anorectal dose-effect relations for late gastrointestinal toxicity following external beam radiotherapy for prostate cancer in the FLAME trial. Radiother Oncol 162:98\u2013104","journal-title":"Radiother Oncol"},{"key":"2799_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.12.012","author":"VH Groen","year":"2021","unstructured":"Groen VH, Haustermans K, Pos FJ et al (2021) Patterns of failure following external beam radiotherapy with or without an additional focal boost in the randomized controlled FLAME trial for localized prostate cancer. Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2021.12.012","journal-title":"Eur Urol"},{"key":"2799_CR82","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.ijrobp.2017.01.219","volume":"97","author":"MH Schild","year":"2017","unstructured":"Schild MH, Schild SE, Wong WW et al (2017) A prospective trial of intensity modulated radiation therapy (IMRT) incorporating a simultaneous integrated boost for prostate cancer: long-term outcomes compared with standard image guided IMRT. Int J Radiat Oncol Biol Phys 97:1021\u20131025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2799_CR83","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.ijrobp.2023.06.250","volume":"117","author":"WL Ong","year":"2023","unstructured":"Ong WL, Cheung P, Chung H et al (2023) To boost or not to boost: pooled analyses from 2-fraction SABR trials for localized prostate cancer. Int J Radiat Oncol Biol Phys 117:1153\u20131162","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2799_CR84","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.radonc.2017.12.022","volume":"127","author":"EM Monninkhof","year":"2018","unstructured":"Monninkhof EM, van Loon JWL, van Vulpen M et al (2018) Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: toxicity in the FLAME randomized controlled trial. Radiother Oncol 127:74\u201380","journal-title":"Radiother Oncol"},{"key":"2799_CR85","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ijrobp.2023.07.044","volume":"118","author":"K Menne Guricova","year":"2024","unstructured":"Menne Guricova K, Groen V, Pos F et al (2024) Risk modeling for individualization of the FLAME focal boost approach in external beam radiation therapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 118:66\u201373","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2799_CR86","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ et al (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395:1208\u20131216","journal-title":"Lancet"},{"key":"2799_CR87","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/iju.14497","volume":"28","author":"S Yoshida","year":"2021","unstructured":"Yoshida S, Takahara T, Arita Y et al (2021) Whole-body diffusion-weighted magnetic resonance imaging: diagnosis and follow up of prostate cancer and beyond. Int J Urol 28:502\u2013513","journal-title":"Int J Urol"},{"key":"2799_CR88","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/s41585-019-0213-3","volume":"16","author":"H Tharmalingam","year":"2019","unstructured":"Tharmalingam H, Choudhury A, Van Herk M et al (2019) New approaches for effective and safe pelvic radiotherapy in high-risk prostate cancer. Nat Rev Urol 16:523\u2013538","journal-title":"Nat Rev Urol"},{"key":"2799_CR89","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03282.JCO2003282","author":"V Murthy","year":"2021","unstructured":"Murthy V, Maitre P, Kannan S et al (2021) Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.20.03282.JCO2003282","journal-title":"J Clin Oncol"},{"key":"2799_CR90","doi-asserted-by":"publisher","first-page":"7859","DOI":"10.1002\/cam4.5554","volume":"12","author":"K Nakamura","year":"2023","unstructured":"Nakamura K, Norihisa Y, Ikeda I et al (2023) Ten-year outcomes of whole-pelvic intensity-modulated radiation therapy for prostate cancer with regional lymph node metastasis. Cancer Med 12:7859\u20137867","journal-title":"Cancer Med"},{"key":"2799_CR91","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.ijrobp.2019.09.044","volume":"106","author":"H Tharmalingam","year":"2020","unstructured":"Tharmalingam H, Tsang Y, Choudhury A et al (2020) External beam radiation therapy (EBRT) and high-dose-rate (HDR) brachytherapy for intermediate and high-risk prostate cancer: the impact of EBRT volume. Int J Radiat Oncol Biol Phys 106:525\u2013533","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2799_CR92","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ijrobp.2019.12.044","volume":"107","author":"Y Alayed","year":"2020","unstructured":"Alayed Y, Davidson M, Liu S et al (2020) Evaluating the tolerability of a simultaneous focal boost to the gross tumor in prostate SABR: a toxicity and quality-of-life comparison of two prospective trials. Int J Radiat Oncol Biol Phys 107:136\u2013142","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2799_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.02.054","author":"OA Houlihan","year":"2023","unstructured":"Houlihan OA, Redmond K, Fairmichael C et al (2023) A randomised feasibility trial of stereotactic prostate radiotherapy with or without elective nodal irradiation in high-risk localised prostate cancer (SPORT trial). Int J Radiat Oncol Biol Phys. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.02.054","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2799_CR94","first-page":"22","volume":"25","author":"I Syndikus","year":"2020","unstructured":"Syndikus I, Cruickshank C, Staffurth J et al (2020) PIVOTALboost: a phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (CRUK\/16\/018). Clin Transl Radiat Oncol 25:22\u201328","journal-title":"Clin Transl Radiat Oncol"},{"key":"2799_CR95","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.ijrobp.2021.10.137","volume":"113","author":"R Hannan","year":"2022","unstructured":"Hannan R, Salamekh S, Desai NB et al (2022) SABR for high-risk prostate cancer: a prospective multilevel MRI-based dose escalation trial. Int J Radiat Oncol Biol Phys 113:290\u2013301","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02799-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02799-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02799-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T18:14:48Z","timestamp":1757182488000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02799-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,8]]},"references-count":95,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2799"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02799-x","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,8]]},"assertion":[{"value":"3 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Rihito Aizawa reported receiving honoraria for lectures or presentations from Janssen Pharmaceutical K.K., Ferring Pharmaceuticals Co., Ltd., Astellas Pharma Inc., Bayer Yakuhin, Ltd. and Takeda Pharmaceutical Co., Ltd. Takashi Mizowaki reported receiving grants or scholarship donation from Hitachi High-Tech Corporation, research fund from Varian Medical Systems, Hitachi High-Tech Corporation, and Brainlab AG, and honoraria for lectures or presentations from Varian Medical Systems, Novartis Pharma K.K. and Janssen Pharmaceutical K.K.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}